Clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma

Hepatology Research

Volumn 43, Issue 5, 2013, Pages 481-487

  Ijichi, Hideki ^a   Shirabe, Ken ^a   Taketomi, Akinobu ^a   Yoshizumi, Tomoharu ^a   Ikegami, Toru ^a   Mano, Youhei ^a   Aishima, Shinichi ^a   Abe, Koichiro ^b   Honda, Hiroshi ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

18F fluorodeoxyglucose positron emission tomography; Combined hepatocellular and cholangiocarcinoma; Hepatocellular carcinoma; Sarcomatous hepatocellular carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDIUM CHAIN TRIACYLGLYCEROL; SILVER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; FOLLOW UP; HEALTH CARE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER SARCOMA; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

EID: 84876996286     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01107.x     Document Type: Article

References (26)

1. Rigo P, Paulus P, Kaschten BJ etal. Oncological application of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
2. Iglehart JK. The new era of medical imaging - progress and pitfalls. N Engl J Med 2006; 354: 2822-2828.
3. Trojan J, Schroeder O, Raedle J etal. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314-3319.
4. Khan MA, Combs CS, Brunt EM etal. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32: 792-797.
5. Torizuka T, Tamaki N, Inokuma T etal. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811-1817.
6. Hatano E, Ikai I, Higashi T etal. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006; 30: 1736-1741.
7. Seo S, Hatano E, Higashi T etal. Fluorine-18-fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007; 13: 427-433.
8. Ng IO. Prognostic significance of pathological and biological factors in hepatocellular carcinoma. J Gastroenterol Hepatol 1998; 13: 666-670.
9. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J Gastroenterol 2009; 44 (Suppl 19): 112-118.
10. Sato M, Watanabe Y, Lee T etal. Well-differentiated hepatocellular carcinoma: clinicopathological features and results of hepatic resection. Am J Gastroenterol 1995; 90: 112-116.
11. Oishi K, Itamoto T, Amano H etal. Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol 2007; 95: 311-316.
12. Ikebe T, Wakasa K, Sasaki M etal. Hepatocellular carcinoma with chondrosarcomatous variation: case report with immunohistochemical findings, and review of the literature. J Hepatobiliary Pancreat Surg 1998; 5: 217-220.
13. Maeda T, Adachi E, Kajiyama M, Takenaka K, Sugimachi K, Tsuneyoshi M. Spindle cell hepatocellular carcinoma: a clinicopahtologic and immunohistochemical analysis of 15 cases. Cancer 1996; 77: 51-57.
14. Tsujimoto M, Aozasa K, Nakajima Y, Kariya M. Hepatocellular carcinoma with sarcomatous proliferation showing an unusual and widespread metastasis. Acta Pathol Jpn 1984; 34: 839-845.
15. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver Cancer Study Group of Japan. Ann Surg 1990; 211: 277-287.
16. Jarnagin WR, Weber S, Tickoo SK etal. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 2002; 94: 2040-2046.
17. Yano Y, Yamamoto J, Kosuge T etal. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 2003; 33: 283-287.
18. Nishie A, Yoshimitsu K, Asayama Y etal. Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT; comparison with histologic findings. Am J Roentgenol 2005; 184: 1157-1162.
19. Breitenstein S, Apestegui C, Clavien PA. Positron emission tomography (PET) for cholangiocarcinoma. HPB 2008; 10: 120-121.
20. Kakizoe S, Kojiro M, Nakashima T. Hepatocellular carcinoma with sarcomatous change: clinicopathologic and immunohistochemical studies of 14 autopsy cases. Cancer 1987; 59: 310-316.
21. Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K. Hepatocellular carcinoma with sarcomatous change: a special reference to relationship with anticancer therapy. Cancer Chemother Pharmacol 1989; 23: 4-8.
22. Honda H, Hayashi T, Yoshida K etal. Hepatocellular carcinoma with sarcomatous change: characteristic findings of two-phased incremental CT. Abdom Imaging 1996; 21: 37-40.
23. Koh KC, Lee H, Choi MS etal. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 2005; 189: 120-125.
24. Aishima S, Kuroda Y, Asayama Y etal. Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. Hum Pathol 2006; 47: 283-291.
25. Kim KH, Lee SG, Park EH etal. Surgical treatments and prognosis of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol 2009; 16: 623-629.
26. Riedl CC, Akhurst T, Larson S etal. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007; 48: 771-775.